Navigation Links
Chiltern Appoints Steve Albrecht to Support Further Expansion in Late Phase
Date:10/8/2007

LONDON, Oct. 9 /PRNewswire/ -- Chiltern, a leading global clinical research organization, has announced the appointment of Steve Albrecht to the role of Director, Business Operations, Late Phase. Steve Albrecht brings over 20 years of CRO industry experience to his new appointment; previously he held executive management positions with other major CROs and recently Registrat in late phase development.

Mr. Albrecht will be providing leadership for the development, implementation and execution of Chiltern's Late Phase strategies.

"I am delighted to join the current excellent staff at Chiltern," said Steve "and I look forward to further developing the Late Phase division in order to provide our sponsors with the best available options for the conduct of their Phase IIIb/IV studies. Post marketing studies pose an excellent opportunity to combine the knowledge gained in early phase development with well-designed and implemented late phase programs. Today, FDA and the pharmaceutical industry are mandating an ever-increasing number of post-marketing trials to follow products in a real-world setting. These studies require high quality standards yielding high quality data."

"I am delighted that Steve has joined Chiltern," commented James Esinhart, Executive Vice President, Biometrics & Late Phase. "Steve's strong background in Late Phase will add strength to our group and provide sponsors with services in the design and execution of both commercial programs and risk management programs for their marketed products."

About Chiltern:

Established in 1982, Chiltern is a leading global Contract Research Organization with extensive experience conducting and staffing international Phase I to Phase IV clinical trials across a broad therapeutic range for a wide variety of clients. Chiltern employs more than 1000 people with 18 offices across the United States, Europe and in India. Chiltern provides services including Early Phase, Global Clinical Development, Late Phase, Biometrics, Medical and Regulatory Affairs and Resourcing Solutions.

For More Information Contact:

Catherine Lemercier Richard Baptista

Chiltern International, Inc. Chiltern International Ltd.

2111 Palomar Airport Road 171 Bath Road

Suite 200 Slough

Carlsbad Berkshire

CA 92011 SL1 4AA

USA UNITED KINGDOM

Tel: 1 (760) 707 5025 Tel: 44 (0) 1753 512 000

Fax: 1 (760) 707 5022 Fax: 44 (0) 1753 511 116

Email: Catherine.Lemercier@chiltern.com Email:

Richard.Baptista@chiltern.com

Chiltern: Understanding


'/>"/>
SOURCE Chiltern
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Steve Tyler Tells All About His Beauty Regime
2. Prince Charles lends support to Alternative Medicine
3. Support therapy helps breast cancer patients
4. Evidence supporting H.pylori eradication
5. Further support for use of statins in Alzheimer’s disease
6. Toxin injections support stroke associated spasticity
7. Support for patients with Leg Pain
8. Vitamin E supports Female Hearts
9. Injection supports Heart Devices
10. Modified antibiotic may support fight cancer
11. WHO To Support Public Health Threats
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... ... May 24, 2016 , ... Mental health watchdog Citizens Commission on ... and renowned professor of psychiatry Thomas Szasz, is continuing its protest against the use ... Death” exhibit in Atlanta, Georgia. The opening of the exhibit follows CCHR’s recent protest ...
(Date:5/24/2016)... , ... May 24, 2016 , ... Loma Linda University ... new adult hospital and expanded Children’s Hospital. Over 3,000 people looked on as the ... Check out the event photo slidehsow. , During the program, Richard H. Hart, ...
(Date:5/24/2016)... ... , ... Backed by decades of experience, Metroloji Okulu works ... best suited solution to meet regulatory requirements. Their professional staff also performs on-site ... , Metroloji Okulu specializes in MadgeTech’s line of medical and pharmaceutical data ...
(Date:5/24/2016)... (PRWEB) , ... May 24, 2016 , ... Growing in ... growing trend, more gluten-free products are available and easily accessible. Whether someone chooses to ... to cater to a certain diet, King Kullen Grocery stocks their shelves with many ...
(Date:5/24/2016)... ... May 24, 2016 , ... ... by 9.3 million people, or 10% over last year, according to data in ... under group policies was comparatively stable, with a slight decrease in risk-based groups ...
Breaking Medicine News(10 mins):
(Date:5/23/2016)... York , May 23, 2016 ... report titled, " Exocrine Pancreatic Insufficiency Market - Global ... - 2023 ." According to the report, the exocrine ... CAGR of 8.3% from 2015 to 2023 to reach ... (EPI) is a condition characterized by the deficiency of ...
(Date:5/23/2016)... -- Non-invasive diagnostic test realizes the potential ... to be presented at Yissum’s booth, at IATI-BIOMED 2016 ... of the Hebrew University of Jerusalem announced today ... Ventures MKI, the technology investment arm of Morris Kahn ... for early detection of multiple diseases by analyzing circulating ...
(Date:5/23/2016)... 2016   Purdue Pharma L.P.  today announced ... with Egalet Corporation and Acura Pharmaceuticals, Inc. that ... the agreement the companies will exchange valuable patent ... companies to develop and sell several opioid pain ... reflects the commitment of Purdue Pharma to seek ...
Breaking Medicine Technology: